- Successful HCV clearance among patients with type 2 diabetes mellitus (T2DM) is associated with significantly reduced odds of acute coronary syndrome (ACS), end-stage renal disease (ESRD), ischemic stroke, and retinopathy.
- Benefit observed independent of cirrhosis status.
Why this matters
- Despite the complex interrelationship of HCV and diabetes, the effect of antiviral therapy on diabetes-related complications has remained largely unknown.
- Data for 1395 HCV-infected patients with T2DM (mean age, 59.4 years) obtained from the 2006-2016 Chronic Hepatitis Cohort Study (CHeCS); 441 were cirrhotic.
- 52% received interferon (IFN) or direct-acting antiviral (DAA) regimens; rate of sustained virologic response at 12 weeks posttherapy (SVR12), 75%.
- Median follow-up: 2.7 years for ACS, ESRD, and stroke; 2.4 years for retinopathy.
- Funding: CHeCS is funded by the CDC and Gilead Pharmaceuticals.
- After propensity-score adjustment for selection bias, SVR12 significantly reduced risk for complications vs no treatment (all P<.001>
- ACS: subHR (sHR)=0.36.
- ESRD: sHR=0.46.
- Stroke: sHR=0.34.
- Retinopathy: sHR=0.24.
- ACS: sHR=0.10 (P<.001>
- ESRD: sHR=0.31 (P=.003).
- Stroke: sHR=0.26 (P=.008).
- Retinopathy: sHR=0.39 (P=.006).
- Observational data, reliance on ICD9/10 codes.